Denali Therapeutics Inc. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Denali Therapeutics Inc. (DNLI) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 28.33 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2026-08-06
- Denali Therapeutics Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2026-06-30 was 28.33M shares, a 8.78% increase year-over-year.
- Denali Therapeutics Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2026-03-31 was 28.33M shares, a 8.78% increase year-over-year.
- Denali Therapeutics Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-09-30 was 26.05M shares, a 0.00% change year-over-year.
- Denali Therapeutics Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-06-30 was 26.05M shares, a 0.00% change year-over-year.
- Denali Therapeutics Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2025 was 26.18M shares, a 19.82% increase from fiscal 2024.
- Denali Therapeutics Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2024 was 21.85M shares.
- Denali Therapeutics Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2023 was 0.00 shares.
- Denali Therapeutics Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2022 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | 28.33M shares 10-Q · filed 2026-08-06 | 28.33M shares 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | 28.33M shares 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 26.18M shares 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 26.05M shares 10-Q · filed 2025-11-06 | 26.05M shares 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | 26.05M shares 10-Q · filed 2026-08-06 | 26.05M shares 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | 26.05M shares 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 21.85M shares 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 26.05M shares 10-Q · filed 2025-11-06 | 20.44M shares 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | 26.05M shares 10-Q · filed 2025-08-11 | 17.60M shares 10-Q · filed 2025-08-11 | ||
| 2023-12-31 | 0.00 shares 10-K · filed 2026-02-26 | |||
| 2022-12-31 | 0.00 shares 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |